NEW YORK and LONDON, March 1, 2016 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ: AKTX), an emerging growth, development-stage biopharmaceutical company, announced today that Gur Roshwalb, M.D., Chief Executive Officer, will present and participate in a question-and-answer session at the Cowen and
NEW YORK and LONDON, February 17, 2016 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ: AKTX), an emerging growth, development-stage biopharmaceutical company, announced today that members of its management team will participate in the 2016 SunTrust Robinson Humphrey Orphan Drug Day on Tuesday,
NEW YORK and LONDON, January 29, 2016 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ: AKTX), an emerging growth, development-stage biopharmaceutical company, announced today the approval by the UK Medicines & Healthcare products Regulatory Agency (MHRA) to conduct a Phase IB multiple ascending
NEW YORK and LONDON, Jan. 27, 2016 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ: AKTX ), an emerging growth, development-stage biopharmaceutical company, announced today that members of its management team will participate in the 2016 Canaccord Genuity Rare Disease, BioPharma One-On-One Day on
NEW YORK and LONDON, Jan. 05, 2016 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ: AKTX ), an emerging growth, development-stage biopharmaceutical company, announced an update from its 28 day non-human primate (NHP) safety study that Coversin demonstrated complete inhibition of complement C5
NEW YORK and LONDON, Dec. 07, 2015 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ: AKTX ), an emerging growth, development-stage biopharmaceutical company, provided an update from its 28 day non-human primate (NHP) safety study at the International PNH Interest Group 10th Annual Scientific Meeting
NEW YORK and LONDON, Nov. 05, 2015 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ: AKTX ), an emerging growth, development-stage biopharmaceutical company, announced today that new data on Coversin efficacy in eculizumab resistant patients will be presented at the 57th American Society of
NEW YORK and LONDON, Sept. 21, 2015 (GLOBE NEWSWIRE) -- Akari Therapeutics (formerly known as Celsus Therapeutics plc) (NASDAQ: AKTX ), an emerging growth, development-stage biopharmaceutical company, announced today that it has closed a previously announced private placement financing with a
EW YORK, NY and LONDON, UNITED KINGDOM--(Marketwired - July 13, 2015) - Celsus Therapeutics ( CLTX ) and Volution Immuno Pharmaceuticals SA today announced that they have entered into a Definitive Exchange Agreement, pursuant to which privately-held Volution Immuno Pharmaceuticals
NEW YORK and LONDON, Feb. 17, 2015 (GLOBE NEWSWIRE) -- Celsus Therapeutics (Nasdaq: CLTX ), an emerging growth, development-stage biopharmaceutical company, announced today the results from C012013, a Phase II, double-blind, parallel-group, vehicle-controlled study to evaluate the safety and